Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 15/20 | 0.59 |
| ▸ | HSD17B2 | P37059 | 14/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605885 | 0.86 | ESR1 (0.56) | HSD17B1HSD17B2ESR1ESR2MAPT | |
| SCHEMBL3608422 | 0.83 | NPSR1 (0.43) | HSD17B1HSD17B2MAPT | |
| SCHEMBL3610616 | 0.83 | NPSR1 (0.48) | HSD17B1HSD17B2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3601375 | 0.79 | MAPT (0.46) | MAPT | |
| SCHEMBL3599918 | 0.78 | MAPK14 (0.40) | ESR1ESR2MAPT | |
| SCHEMBL3597248 | 0.78 | HSD17B1 (0.59) | HSD17B1HSD17B2CYP3A4ESR1ESR2 | |
| SCHEMBL3592991 | 0.77 | NPSR1 (0.40) | ESR1ESR2MAPT | |
| SCHEMBL3603115 | 0.76 | ALDH1A1 (0.45) | CYP2C19CYP2C9MAPT | |
| SCHEMBL3596099 | 0.73 | HSD17B1 (0.64) | HSD17B1HSD17B2CYP3A4ESR1ESR2 | |
| SCHEMBL3603955 | 0.72 | MAPT (0.44) | CYP2C19ESR1ESR2CYP2C9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835476-B2 | Synthesis of novel antimicrobials | WU FAN (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20100076028-A1 | Design and Synthesis of Novel Antimicrobials | WU FAN | 2010-03-25 | — | — | US | disclosed |
| WO-2006092059-A1 | DESIGN AND SYNTHESIS OF NOVEL ANTIMICROBIALS | WU FAN (CA) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076028-A1 | Design and Synthesis of Novel Antimicrobials | MLX, LPXN, TPX2 | HSD17B1 3041/4885HSD17B2 3760/4885CYP3A4 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.